USMLE Step 1 practice question: Tumor lysis syndrome: rasburicase mechanism and G6PD deficiency
USMLE Step 1Hematology/OncologyPharmacology
This drug lowers serum uric acid by which of the following mechanisms?
- Inhibition of xanthine oxidase
- Oxidation of uric acid to allantoin
- Inhibition of tubular urate reabsorption
- Inhibition of neutrophil microtubule assembly
- Alkalinization of the urine
Show answer and explanation
Correct answer: B. Oxidation of uric acid to allantoin
Hyperkalemia, hyperphosphatemia, hypocalcemia, hyperuricemia and acute kidney injury shortly after chemotherapy for a rapidly proliferating tumor such as Burkitt lymphoma define tumor lysis syndrome. Lysed cells release potassium, phosphate and nucleic acids; purines are degraded to hypoxanthine and xanthine and then, by xanthine oxidase, to uric acid. Phosphate binds calcium, causing hypocalcemia, and uric acid and calcium phosphate crystals obstruct the tubules. Hyperkalemia and hypocalcemia cause arrhythmias, cramps, tetany and seizures.
Rasburicase is a recombinant urate oxidase (uricase), an enzyme most mammals have but humans lost during evolution. It oxidizes uric acid to allantoin, which is far more water soluble and is readily excreted, so it removes uric acid that is already present and lowers levels within hours. The reaction also produces hydrogen peroxide; in glucose-6-phosphate dehydrogenase (G6PD) deficiency, red cells cannot regenerate enough reduced glutathione to neutralize it, and severe hemolysis and methemoglobinemia result. G6PD status must therefore be checked first. Rasburicase keeps degrading uric acid in drawn blood at room temperature, so samples are sent on ice.
Allopurinol and febuxostat inhibit xanthine oxidase; they prevent new uric acid formation but do not remove existing uric acid, and xanthine can accumulate. They are used for prevention in lower-risk patients, whereas rasburicase is preferred for high-risk patients or established hyperuricemia. Urine alkalinization is no longer recommended because it promotes calcium phosphate precipitation.
Why the other options are wrong
- A. Inhibition of xanthine oxidase — Xanthine oxidase inhibitors (allopurinol, febuxostat) block new uric acid formation but do not rapidly lower uric acid already present.
- C. Inhibition of tubular urate reabsorption — Uricosurics such as probenecid inhibit urate reabsorption (URAT1) and increase urinary uric acid, which would worsen crystal nephropathy in tumor lysis syndrome.
- D. Inhibition of neutrophil microtubule assembly — Colchicine inhibits microtubule assembly in neutrophils and treats gouty inflammation; it does not lower serum uric acid.
- E. Alkalinization of the urine — Urine alkalinization increases uric acid solubility but does not remove uric acid and promotes calcium phosphate precipitation; it is no longer recommended.
Key point
Rasburicase, a recombinant urate oxidase, rapidly lowers uric acid in tumor lysis syndrome by converting it to soluble allantoin and is contraindicated in G6PD deficiency because it generates hydrogen peroxide.
Memory hook
Rasburicase razes uric acid to allantoin, but its hydrogen peroxide wrecks G6PD-deficient red cells, so check G6PD first.
15 free bank questions a day, exam-length timed blocks, spaced repetition and 3D anatomy — in English and Russian.
Play free